CTOR Stock Citius Oncology (CTOR, $0.93) is a top weekly gainer for penny stocks, rising +23.88%
at Tickeron.com
Loading...
A.I.dvisor analyzed 84 other stocks in the Pharmaceuticals: Generic Industry over the last week and discovered that of them (3) exhibited an Uptrend while of them (6) exhibited a Downtrend.
CTOR in upward trend: 10-day moving average crossed above 50-day moving average on August 12, 2026
The 10-day moving average for CTOR crossed bullishly above the 50-day moving average on August 12, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 5 of 6 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 31, 2026. You may want to consider a long position or call options on CTOR as a result. In 35 of 55 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for CTOR just turned positive on September 04, 2026. Looking at past instances where CTOR's MACD turned positive, the stock continued to rise in 19 of 35 cases over the following month. The odds of a continued upward trend are 54%.
Following a +9.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where CTOR advanced for three days, in 83 of 106 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 41 of 195 cases where CTOR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 21%.
Bearish Trend Analysis
The 10-day RSI Indicator for CTOR moved out of overbought territory on September 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 10 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTOR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
CTOR broke above its upper Bollinger Band on September 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.403) is normal, around the industry mean (46.728). P/E Ratio (0.000) is within average values for comparable stocks, (93.360). CTOR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.931). CTOR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (12.063) is also within normal values, averaging (176.516).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CTOR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTOR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.